Could Event Related Potentials be a Key Prognostic Biomarker of Alzheimer’s Disease?

Alzheimer’s Disease (AD) presents substantial biological complexity, highlighting the need for system‑level innovative strategies to advance drug and therapeutic target discovery. This Special Issue, “Artificial Intelligence-Driven Drug and Therapeutic Target Discovery in Alzheimer’s Disease,” explores the expanding role of Artificial Intelligence (AI) in transforming AD research. Featured contributions will demonstrate ...read more

Patients with non-amnestic atypical variants of Alzheimer’s disease show considerable heterogeneity in clinical characteristics, including visual, language and behavioral impairments, and often have a young age onset. Current clinical trials for anti-amyloid therapies do not sufficiently account for this heterogeneity, and it is unclear whether current treatments tested in amnestic ...read more

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia globally. While amyloid-beta (Aβ) accumulation and tau pathology have long dominated mechanistic models of AD, emerging research underscores the central role of the gut-brain-microbiota axis in influencing disease onset, progression, and potentially, treatment outcomes. This ...read more

Alzheimer’s disease is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Alzheimer’s disease affects brain memory and other cognitive functions. Therefore, the early detection and diagnosis of Alzheimer’s disease are crucial in developing effective treatments and improving the quality of life for patients. Recent years have seen ...read more